Cargando…
Interleukin Enhancer-binding Factor 3/NF110 Is a Target of YM155, a Suppressant of Survivin
Survivin is responsible for cancer progression and drug resistance in many types of cancer. YM155 selectively suppresses the expression of survivin and induces apoptosis in cancer cells in vitro and in vivo. However, the mechanism underlying these effects of YM155 is unknown. Here, we show that a tr...
Autores principales: | , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The American Society for Biochemistry and Molecular Biology
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3394938/ https://www.ncbi.nlm.nih.gov/pubmed/22442257 http://dx.doi.org/10.1074/mcp.M111.013243 |
_version_ | 1782237909366079488 |
---|---|
author | Nakamura, Naoto Yamauchi, Tomohiro Hiramoto, Masashi Yuri, Masatoshi Naito, Masanori Takeuchi, Masahiro Yamanaka, Kentaro Kita, Aya Nakahara, Takahito Kinoyama, Isao Matsuhisa, Akira Kaneko, Naoki Koutoku, Hiroshi Sasamata, Masao Yokota, Hiroyuki Kawabata, Shigeki Furuichi, Kiyoshi |
author_facet | Nakamura, Naoto Yamauchi, Tomohiro Hiramoto, Masashi Yuri, Masatoshi Naito, Masanori Takeuchi, Masahiro Yamanaka, Kentaro Kita, Aya Nakahara, Takahito Kinoyama, Isao Matsuhisa, Akira Kaneko, Naoki Koutoku, Hiroshi Sasamata, Masao Yokota, Hiroyuki Kawabata, Shigeki Furuichi, Kiyoshi |
author_sort | Nakamura, Naoto |
collection | PubMed |
description | Survivin is responsible for cancer progression and drug resistance in many types of cancer. YM155 selectively suppresses the expression of survivin and induces apoptosis in cancer cells in vitro and in vivo. However, the mechanism underlying these effects of YM155 is unknown. Here, we show that a transcription factor, interleukin enhancer-binding factor 3 (ILF3)/NF110, is a direct binding target of YM155. The enhanced survivin promoter activity by overexpression of ILF3/NF110 was attenuated by YM155 in a concentration-dependent manner, suggesting that ILF3/NF110 is the physiological target through which YM155 mediates survivin suppression. The results also show that the unique C-terminal region of ILF3/NF110 is important for promoting survivin expression and for high affinity binding to YM155. |
format | Online Article Text |
id | pubmed-3394938 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2012 |
publisher | The American Society for Biochemistry and Molecular Biology |
record_format | MEDLINE/PubMed |
spelling | pubmed-33949382012-07-16 Interleukin Enhancer-binding Factor 3/NF110 Is a Target of YM155, a Suppressant of Survivin Nakamura, Naoto Yamauchi, Tomohiro Hiramoto, Masashi Yuri, Masatoshi Naito, Masanori Takeuchi, Masahiro Yamanaka, Kentaro Kita, Aya Nakahara, Takahito Kinoyama, Isao Matsuhisa, Akira Kaneko, Naoki Koutoku, Hiroshi Sasamata, Masao Yokota, Hiroyuki Kawabata, Shigeki Furuichi, Kiyoshi Mol Cell Proteomics Research Survivin is responsible for cancer progression and drug resistance in many types of cancer. YM155 selectively suppresses the expression of survivin and induces apoptosis in cancer cells in vitro and in vivo. However, the mechanism underlying these effects of YM155 is unknown. Here, we show that a transcription factor, interleukin enhancer-binding factor 3 (ILF3)/NF110, is a direct binding target of YM155. The enhanced survivin promoter activity by overexpression of ILF3/NF110 was attenuated by YM155 in a concentration-dependent manner, suggesting that ILF3/NF110 is the physiological target through which YM155 mediates survivin suppression. The results also show that the unique C-terminal region of ILF3/NF110 is important for promoting survivin expression and for high affinity binding to YM155. The American Society for Biochemistry and Molecular Biology 2012-07 /pmc/articles/PMC3394938/ /pubmed/22442257 http://dx.doi.org/10.1074/mcp.M111.013243 Text en © 2012 by The American Society for Biochemistry and Molecular Biology, Inc. Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) applies to Author Choice Articles |
spellingShingle | Research Nakamura, Naoto Yamauchi, Tomohiro Hiramoto, Masashi Yuri, Masatoshi Naito, Masanori Takeuchi, Masahiro Yamanaka, Kentaro Kita, Aya Nakahara, Takahito Kinoyama, Isao Matsuhisa, Akira Kaneko, Naoki Koutoku, Hiroshi Sasamata, Masao Yokota, Hiroyuki Kawabata, Shigeki Furuichi, Kiyoshi Interleukin Enhancer-binding Factor 3/NF110 Is a Target of YM155, a Suppressant of Survivin |
title | Interleukin Enhancer-binding Factor 3/NF110 Is a Target of YM155, a Suppressant of Survivin |
title_full | Interleukin Enhancer-binding Factor 3/NF110 Is a Target of YM155, a Suppressant of Survivin |
title_fullStr | Interleukin Enhancer-binding Factor 3/NF110 Is a Target of YM155, a Suppressant of Survivin |
title_full_unstemmed | Interleukin Enhancer-binding Factor 3/NF110 Is a Target of YM155, a Suppressant of Survivin |
title_short | Interleukin Enhancer-binding Factor 3/NF110 Is a Target of YM155, a Suppressant of Survivin |
title_sort | interleukin enhancer-binding factor 3/nf110 is a target of ym155, a suppressant of survivin |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3394938/ https://www.ncbi.nlm.nih.gov/pubmed/22442257 http://dx.doi.org/10.1074/mcp.M111.013243 |
work_keys_str_mv | AT nakamuranaoto interleukinenhancerbindingfactor3nf110isatargetofym155asuppressantofsurvivin AT yamauchitomohiro interleukinenhancerbindingfactor3nf110isatargetofym155asuppressantofsurvivin AT hiramotomasashi interleukinenhancerbindingfactor3nf110isatargetofym155asuppressantofsurvivin AT yurimasatoshi interleukinenhancerbindingfactor3nf110isatargetofym155asuppressantofsurvivin AT naitomasanori interleukinenhancerbindingfactor3nf110isatargetofym155asuppressantofsurvivin AT takeuchimasahiro interleukinenhancerbindingfactor3nf110isatargetofym155asuppressantofsurvivin AT yamanakakentaro interleukinenhancerbindingfactor3nf110isatargetofym155asuppressantofsurvivin AT kitaaya interleukinenhancerbindingfactor3nf110isatargetofym155asuppressantofsurvivin AT nakaharatakahito interleukinenhancerbindingfactor3nf110isatargetofym155asuppressantofsurvivin AT kinoyamaisao interleukinenhancerbindingfactor3nf110isatargetofym155asuppressantofsurvivin AT matsuhisaakira interleukinenhancerbindingfactor3nf110isatargetofym155asuppressantofsurvivin AT kanekonaoki interleukinenhancerbindingfactor3nf110isatargetofym155asuppressantofsurvivin AT koutokuhiroshi interleukinenhancerbindingfactor3nf110isatargetofym155asuppressantofsurvivin AT sasamatamasao interleukinenhancerbindingfactor3nf110isatargetofym155asuppressantofsurvivin AT yokotahiroyuki interleukinenhancerbindingfactor3nf110isatargetofym155asuppressantofsurvivin AT kawabatashigeki interleukinenhancerbindingfactor3nf110isatargetofym155asuppressantofsurvivin AT furuichikiyoshi interleukinenhancerbindingfactor3nf110isatargetofym155asuppressantofsurvivin |